Education
About Us
Working with TipRanks
Follow Us
Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
FARN Stock Chart & Stats
Day’s Range― - ―
52-Week Range85.00p - 240.00p
Previous CloseN/A
Volume750.00
Average Volume (3M)27.50K
Market Cap
£210.18M
Enterprise Value66.58M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)2.36M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 27, 2025EPS Estimate
-8.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding111,601,610
10 Day Avg. Volume18,223
30 Day Avg. Volume27,498
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)725.43
Price to Cash Flow (P/CF)-13.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
533.63pPrice Target Upside192.40% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Faron Pharmaceuticals Oy News
PremiumCompany Announcements
Faron Pharmaceuticals’ Bexmarilimab Gains FDA Orphan Drug Designation for MDS
PremiumCompany Announcements
Faron Pharmaceuticals Gains EMA Orphan Drug Status for Bexmarilimab
PremiumCompany Announcements
Faron Pharmaceuticals to Release Financial Results and Host Webcast
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEvidence of unprecedented clinical benefit with bexmarilimab treatment in patients who have failed previous treatments for myelodysplastic syndromes.
Financial PositionWith a strengthened balance sheet, active partnership discussions to fund Phase 3, and increasing recognition of macrophage-targeting immunotherapies, Faron is well-positioned for significant upside.
Regulatory ProgressRegulatory progress further strengthens the case for Bex in MDS, with the FDA granting Fast Track Designation and providing positive feedback on the registrational strategy, potentially expediting the approval timeline.
Bears Say
Development RisksRisks include clinical development risk tied to Bex in multiple tumor types, competitor risk, and novel mechanism risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.22% Insiders
―
Mutual Funds
― Other Institutional Investors
96.78% Public Companies and
Individual Investors
FARN FAQ
What was Faron Pharmaceuticals Oy’s price range in the past 12 months?
Faron Pharmaceuticals Oy lowest share price was 85.00p and its highest was 240.00p in the past 12 months.
What is Faron Pharmaceuticals Oy’s market cap?
Faron Pharmaceuticals Oy’s market cap is £210.18M.
When is Faron Pharmaceuticals Oy’s upcoming earnings report date?
Faron Pharmaceuticals Oy’s upcoming earnings report date is Aug 27, 2025 which is in 161 days.
How were Faron Pharmaceuticals Oy’s earnings last quarter?
Faron Pharmaceuticals Oy released its earnings results on Feb 27, 2025. The company reported -0.093p earnings per share for the quarter, beating the consensus estimate of -0.135p by 0.042p.
Is Faron Pharmaceuticals Oy overvalued?
According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued.
Does Faron Pharmaceuticals Oy pay dividends?
Faron Pharmaceuticals Oy does not currently pay dividends.
What is Faron Pharmaceuticals Oy’s EPS estimate?
Faron Pharmaceuticals Oy’s EPS estimate is -8.49.
How many shares outstanding does Faron Pharmaceuticals Oy have?
Faron Pharmaceuticals Oy has 111,601,610 shares outstanding.
What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?
Faron Pharmaceuticals Oy reported an EPS of -0.093p in its last earnings report, beating expectations of -0.135p. Following the earnings report the stock price went up 1.471%.
Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?
Currently, no hedge funds are holding shares in GB:FARN
---
Company Description
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is a anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.
---
FARN Stock 12 Month Forecast
Average Price Target
533.63p
▲(192.40% Upside)
Technical Analysis
Allergy Therapeutics
―
Scancell Holdings
―
Physiomics
―
Open Orphan Plc
―
OptiBiotix Health
―
Best Analysts Covering FARN
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+1.08%
reiterated a buy rating 8 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +1.08% per trade.
---